Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1126

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Cancer

Interventions

DRUG: MEDI4736 (Durvalumab)
DRUG: Tremelimumab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Gemcitabine

Sponsor

AstraZeneca